Benchmark, the Sheffield-based aquaculture biotechnology company, has agreed to sell its genetics division to Novo Holdings, the largest shareholder in Danish pharmaceutical heavyweight Novo Nordisk, for a value of up to £260 million. The transaction includes an initial payment of £230 million, with an additional contingent consideration of up to £30 million. The deal encompasses … Continue reading First Stingray now Benchmark Genetics, Danish heavyweight strikes again with £260 million deal